HaleonNYSE: HLN

Haleon PLC, a healthcare company listed on the FTSE 100, has had £150 million worth of its shares shorted by Marshall Wace, a hedge fund. This is the first time a short-seller has publicly disclosed their position on Haleon since the company was separated from GSK two years ago.

Haleon plc (NYSE:HLN) Q1 2024 Earnings Conference Call on May 1, 2024 at 4:00 AM ET. Company Participants include Sonya Ghobrial, Head of Investor Relations, and Tobias Hestler, Chief Financial Officer. Conference Call Participants include Rashad Kawan from Morgan Stanley, Guillaume Delmas from UBS, David Hayes from Jefferies, Iain Simpson from Barclays, Bruno Monteyne from Bernstein, Victoria Petrova from Bank of America, Celine Pannuti from JPMorgan, Tom Sykes from Deutsche Bank, Mikheil Omanadze from BNP Paribas Exane, and Chris Pitcher from Redburn. Operator Davin welcomes everyone to the Haleon Q1 2024 Trading Update Conference Call.

Haleon PLC (LSE:HLN, NYSE:HLN), the company behind Advil and Sensodyne, maintained its annual forecast despite a decrease in revenue in the first quarter, which was as anticipated. Organic revenues increased by 3.0% compared to the previous year, with sales volumes and product mix having a negative impact of 2%, primarily due to a milder cold and flu season. This was partly offset by a 5% increase in prices.

Haleon, a consumer healthcare company, reported lower-than-expected revenue in the first quarter of the year, attributed to reduced inventory levels at retailers in the U.S. and a decrease in demand for cold and flu medication following a previous spike.

The announcement that Haleon PLC, the manufacturer of Sensoyde toothpaste, may reduce approximately 435 positions due to the closure of a manufacturing facility has caused a 1.5% increase in its shares. The company, which was previously part of GSK before becoming independent two years ago, intends to shut down a site in Maidenhead within the next two years.

Haleon, a consumer healthcare company, is set to close its manufacturing facility in Britain by 2026, affecting 435 jobs, according to a spokesperson speaking to Reuters on Tuesday.

Haleon is scheduled to announce its first-quarter earnings on 1 May, with UBS increasing its projection for organic sales growth to 3.2% from the previous forecast of 3.0%. While Respiratory Health and Pain Relief face challenging comparisons, the bank anticipates that strong momentum in Oral Health will help offset these challenges.

Haleon PLC (LSE:HLN, NYSE:HLN) said Pfizer Inc (NYSE:PFE, ETR:PFE) had sold a larger than expected amount of its shares overnight, scooping roughly £2.4 billion compared to the £2 billion expected, after the public offering was upsized.  The FTSE 100-listed consumer goods company said the US and international offer had been priced at £3.08 per ordinary share and $7.85 per American Depositary Shares.

Pfizer Inc (NYSE:PFE, ETR:PFE) has confirmed it will sell a large chunk of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), raising over £2 billion (US$2.55bn). Haleon, a former consumer health joint venture between GSK and Pfizer that was spun out in 2022, aims to but £315 million of the shares, it said.